Cargando…

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

OBJECTIVE: To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Electronic databases (PubMed, Embase, Cochrane Library, and Web of Science...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Cheng, Chen, Yu-Pei, Du, Xiao-Jing, Liu, Jin-Qi, Huang, Cheng-Long, Chen, Lei, Zhou, Guan-Qun, Li, Wen-Fei, Mao, Yan-Ping, Hsu, Chiun, Liu, Qing, Lin, Ai-Hua, Tang, Ling-Long, Sun, Ying, Ma, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222274/ https://www.ncbi.nlm.nih.gov/pubmed/30409774 http://dx.doi.org/10.1136/bmj.k4226

Ejemplares similares

Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
por: Hsieh, Ching-Hung, et al.
Publicado: (2022)

The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
por: Tang, Si-Qi, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
por: Shen, Ying-Chun, et al.
Publicado: (2021)

Impact of marital status at diagnosis on survival and its change over time between 1973 and 2012 in patients with nasopharyngeal carcinoma: a propensity score‐matched analysis
por: Xu, Cheng, et al.
Publicado: (2017)

Socioeconomic factors and survival in patients with non‐metastatic head and neck squamous cell carcinoma
por: Xu, Cheng, et al.
Publicado: (2017)

Comparative role of real-world study and traditional randomized controlled trials in head and neck cancer: a literature-based analysis
por: Zhu, Guang-Li, et al.
Publicado: (2021)

The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses
por: Peng, Liang, et al.
Publicado: (2018)

Cancer vaccine: learning lessons from immune checkpoint inhibitors
por: Ye, ZhenLong, et al.
Publicado: (2018)

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients
por: Huang, Cheng-Long, et al.
Publicado: (2018)

Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan
por: Hsu, Jason C., et al.
Publicado: (2018)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
por: Cai, Qi, et al.
Publicado: (2022)

Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
por: Xu, Cheng, et al.
Publicado: (2018)

Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study
por: Lv, Jia-Wei, et al.
Publicado: (2016)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
por: Chen, Jingjie, et al.
Publicado: (2020)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
por: Feng, Jin-Kai, et al.
Publicado: (2022)

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
por: Zhang, Chao, et al.
Publicado: (2022)

Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis
por: Zhang, Fan, et al.
Publicado: (2015)

Immune checkpoint inhibitors win the 2018 Nobel Prize
por: Huang, Pei-Wei, et al.
Publicado: (2019)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
por: Lv, Jia‐Wei, et al.
Publicado: (2018)

A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry
por: Lv, Jia-Wei, et al.
Publicado: (2018)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy
por: Mao, Yan-Ping, et al.
Publicado: (2016)

The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
por: Hsu, Jason C., et al.
Publicado: (2021)

Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis
por: Wang, Xiao‐Hui, et al.
Publicado: (2023)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer
por: Chen, Xiao-Juan, et al.
Publicado: (2021)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Managing Vibration Training Safety by Using Knee Flexion Angle and Rating Perceived Exertion
por: Chuang, Long-Ren, et al.
Publicado: (2021)

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials
por: Guan, Jiaheng, et al.
Publicado: (2022)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis
por: Li, Xin, et al.
Publicado: (2017)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities
por: Guo, Rui, et al.
Publicado: (2015)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4vfvjn5old1nfkga6glhnjrp1l